ReviewJournal of immunology (Baltimore, Md. : 1950)2013
Complement in immune and inflammatory disorders: therapeutic interventions.
Review in Journal of immunology (Baltimore, Md. : 1950), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03316521 (Safety, Tolerability, Pharmacokinetics), which is not on this map. Cited by 131 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) and a Multiple Dose (MD) of the Complement Inhibitor AMY-101. A Prospective, Single-center, Open-label, First-In-Human (FIH) Clinical Study in Healthy Male Volunteers
Who cites it
131 citing papers in PubMed, 233 citations in OpenAlex.
- The black fly salivary protein Simukunin inhibits complement activation through the lectin pathway protease MASP-2.The Journal of biological chemistry · 2026Article
- Combined Red Cell Exchange and Plasma Exchange for Post-Arrest Refractory Cardiorespiratory Failure in Sickle Cell Disease Sparing Extracorporeal Membrane Oxygenation.Journal of medical cases · 2026Article
- Longitudinal multiomics profiling of extracorporeal cross-circulation with pig liver xenografts in human decedents.Nature medicine · 2026Article
- Lipid nanoparticle-mediated Cd14 siRNA delivery ameliorates the acute inflammatory response to intracortical microelectrode implantation.Acta biomaterialia · 2026Article
- Molecular immunopharmacology of traditional Chinese medicine-derived compounds in membranous nephropathy: mechanistic insights into immune aging and kidney essence deficiency.Frontiers in immunology · 2026Review
- The Alzheimer's disease-associated complement receptor 1 variant confers risk by impacting glial phagocytosis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Comprehensive pan-cancer analysis of PPP1R3G reveals its diagnostic, prognostic, and immunotherapeutic implications.Discover oncology · 2025Article
- Characterization of a Long-Acting Anti-Human MASP-2 Antibody for the Treatment of Complement-Related Diseases.Journal of inflammation research · 2025Article
- Genetically Prioritized Plasma Proteins as Candidate Therapeutic Targets for Dry Age-Related Macular Degeneration.Journal of ophthalmology · 2025Article
- Complement-mediated and direct activation of human neutrophils induced byFrontiers in immunology · 2025Article
- Renal Epithelial Complement C3 Expression Affects Kidney Fibrosis Progression.International journal of molecular sciences · 2024Article
- TMT-based proteomics analysis of the blood enriching mechanism of the total Tannins of Gei Herba in mice.Heliyon · 2024Article
- C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complement.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Complement: Functions, location and implications.Immunology · 2023Review
- Article
- Discovery of a Novel Series of Potent, Selective, Orally Available, and Brain-Penetrable C1s Inhibitors for Modulation of the Complement Pathway.Journal of medicinal chemistry · 2023Article
- The role of complement C3 in the outcome of regional myocardial infarction.Biochemistry and biophysics reports · 2023Article
- Acylation-stimulating protein and heart failure progression in arrhythmogenic right ventricular cardiomyopathy.ESC heart failure · 2023Article
- Development and characterization of narsoplimab, a selective MASP-2 inhibitor, for the treatment of lectin-pathway-mediated disorders.Frontiers in immunology · 2023Article
- C5aR1 blockade reshapes immunosuppressive tumor microenvironment and synergizes with immune checkpoint blockade therapy in high-grade serous ovarian cancer.Oncoimmunology · 2023Article
71 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
With the awareness that immune-inflammatory cross-talk is at the heart of many disorders, the desire for novel immunomodulatory strategies in the therapy of such diseases has grown dramatically. As a prime initiator and important modulator of immunological and inflammatory processes, the complement system has emerged as an attractive target for early and upstream intervention in inflammatory diseases and has moved into the spotlight of drug discovery. Although prevalent conditions such as age-related macular degeneration have attracted the most attention, the diverse array of complement-mediated pathologies, with distinct underlying mechanisms, demands a multifaceted arsenal of therapeutic strategies. Fortunately, efforts in recent years have not only introduced the first complement inhibitors to the clinic but also filled the pipelines with promising candidates. With a focus on immunomodulatory strategies, in this review we discuss complement-directed therapeutic concepts and highlight promising candidate molecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.